Int Neurourol J.  2016 Nov;20(Suppl 2):S131-S140. 10.5213/inj.1632740.370.

Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?

• Tran P
• Nguyen C
• Klempner S

• KMID: 2362506
• DOI: http://doi.org/10.5213/inj.1632740.370

Abstract

Phosphatidylinositol-3-kinase (PI3K) pathway signaling is an established oncogenic signal transduction pathway implicated in multiple malignancies. Therapeutic targeting of PI3K pathway components has improved outcomes in chronic lymphocytic leukemia, kidney cancer, breast cancer, and neuroendocrine tumors. Gastric cancers harbor some of the highest rates of oncogenic alterations in PI3K but attempts to translate this genomic observation have met with limited clinical success and novel approaches are needed. In the following review we discuss PI3K signaling, previous preclinical and clinical investigations in gastric cancer, and discuss future strategies aimed at overcoming resistance and improving efficacy. Identification and refinement of molecular tumor subtypes, development of predictive biomarkers along, and rational drug combination strategies are key to capitalizing on the therapeutic potential of PI3K pathway directed therapies in gastric cancers.

Keyword

PIK3CA portein; Stomach Neoplasms; Molecular Targeted Therapies; AKT oncogene protein; mTOR protein; Clinical Trial

MeSH Terms

Biomarkers
Breast Neoplasms
Kidney Neoplasms
Leukemia, Lymphocytic, Chronic, B-Cell
Molecular Targeted Therapy
Neuroendocrine Tumors
Oncogene Protein v-akt
Signal Transduction
Stomach Neoplasms*
TOR Serine-Threonine Kinases
Biomarkers
Oncogene Protein v-akt
TOR Serine-Threonine Kinases